Fulcrum Therapeutics (FULC) Interest Coverage Ratio Growth (3y) (2021 - 2026)
Fulcrum Therapeutics (FULC) Interest Coverage Ratio Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 28.11% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 29.47% |
| 10 | Fulcrum Therapeutics | 286.57 Mn | 286.57 Mn | - | 56.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.91% |
| Dec 31, 2025 | -29.54% |
| Sep 30, 2025 | 61.61% |
| Jun 30, 2025 | 68.22% |
| Mar 31, 2025 | -80.63% |
| Dec 31, 2024 | 24.43% |
| Sep 30, 2024 | -313.24% |
| Jun 30, 2024 | 81.25% |
| Mar 31, 2024 | 33.73% |
| Dec 31, 2023 | 95.30% |
| Sep 30, 2023 | -30.95% |
| Jun 30, 2023 | -123.69% |
| Mar 31, 2023 | -125.98% |
| Dec 31, 2022 | 97.82% |
| Sep 30, 2022 | -9.43% |
| Jun 30, 2022 | -261.43% |
| Mar 31, 2022 | 97.25% |
| Dec 31, 2021 | 94.27% |
| Sep 30, 2021 | 95.51% |